Abstract
Methods Cross-sectional, multicenter, national survey. The following data were collected: age, sex, type of psoriasis, swollen and tender joint counts (SJ 44/TJ 46), ESR (mm/1hora), CRP (mg/dL), DAS28, Psoriasis Global Assessment (PGA), Physician Global Assessment (PhyGA), Patient Global Assessment (PatGA), pharmacological therapy taken (AINEs, glucocorticoids, DAMARDs, and anti-TNFalfa therapy), Visual Analogue Scale (VAS) of pain, Disease impact as measured by VAS in the personal, occupational and social spheres, Health Assessment Questionnaire (HAQ) and Dermatology Life Quality Index (DLQI).
Highlights
Twenty four percent of patients had a moderate-severe extent of PsA as measured by Psoriasis Global Assessment (PGA)
Of 173 patients from whom DAS28 was available, 38% were en remission (DAS282.63.2). 98.6% of patients were taken drugs for treatment of psoriatic arthritis: 21% oral glucocorticoids (
Disease impact measured by Visual Analogue Scale (VAS) in the personal sphere was higher in females than in males (31.2 (2537.4) vs 22.1 (16.7-27.5); p
Summary
National survey of patients with psoriatic arthritis in Spain: disease activity, pharmacological therapy and impact on quality of life From 5th European Workshop on Immune-Mediated Inflammatory Diseases Sitges-Barcelona, Spain. Objective To evaluate disease activity, management with pharmacological therapy and the impact on functional capacity and quality of life of psoriatic arthritis in Spain.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
